No strict restrictions, but maintaining a balanced diet enhances the effectiveness of the supplement
In addition, BPC-157 has not been approved by the U.S
Cancelled oral trial (2015-2016): A Phase I study registered in Mexico (PCO-02 / Bepecin) evaluated oral BPC-157 tablets for safety and pharmacokinetics in 42 healthy volunteers
Statements Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Wernicke encephalopathy exemplifies the importance of vigilance for rare NAEs
In some embodiments, the amount of thickening agent in any formulation or composition described herein is about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 5.5%, about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about 8.5%, about 9.0%, about 9.5%, about 10%, or about 15%